EPISODE · Mar 10, 2026 · 7 MIN
33. Three Key Blood Tests
from Elton’s Stroke Story: The Surprising Science of Recovery and Prevention · host Elton Sherwin
ApoB, Lipoprotein(a), and C-reactive protein are the three tests that can help you prevent strokes and heart attacks that are often missed in standard blood work:1. ApoB (Apolipoprotein B)Superior Accuracy: ApoB is considered one of the best biomarkers for heart disease risk, as it measures the actual number of all atherogenic (plaque-forming) particles in your bloodBetter than LDL: Traditional cholesterol tests measure the total weight of cholesterol, which can be misleading. Because particles vary in size, you could have a "normal" LDL cholesterol level but a dangerously high number of small, dense particles accumulating in your arteries2. Lipoprotein(a) or Lp(a)Hidden, Powerful Risk: Lp(a) is an inherited, highly dangerous cholesterol particle that carries inflammatory proteins and promotes blood clotting. High levels can double or even triple your risk of a heart attack and greatly increase your risk for stroke and aortic valve stenosisOnce-in-a-Lifetime Test: Because Lp(a) is up to 90% genetically determined, it remains relatively stable throughout your life, meaning it generally only needs to be tested onceExpert Consensus: Cardiology guidelines increasingly recommend that everyone should have their Lp(a) checked at least once to identify high-risk individuals who would otherwise go unnoticed by standard lipid panels3. hs-CRP (High-Sensitivity C-Reactive Protein)Inflammation Marker: Inflammation is a key driver of atherosclerotic cardiovascular diseaseAlong with ApoB and Lp(a), measuring inflammation via hs-CRP is recognized by new guidelines from the American Heart Association and American College of Cardiology as a more accurate predictor of heart disease risk than traditional cholesterol markers.Source: Gemini
NOW PLAYING
33. Three Key Blood Tests
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m